The company is betting its future on a single-use, remotely operated robotic system to disrupt the $15 billion endovascular surgery market. Microbot has collaboration agreements with Corewell Health for LIBERTY development and Emory University for autonomous robotics in endovascular procedures.
Cyborg Score Rationale
The company commenced Limited Market Release in November 2025 with 100% robotic navigation success in a pivotal trial. With $80.2 million in cash and investments as of September 2025, liquidity is strong, but the company faces typical pre-revenue medical device risks.
Top Insights
Nine-month net loss of $9.68 million through September 2025 reflects pre-commercialization R&D and commercial preparation costs.
Emory University Hospital became the first hospital in the world to adopt the LIBERTY System, signaling early validation from prestigious medical institutions.
Three analysts rate MBOT as "Strong Buy" with a 12-month price target of $7.50, representing 262% upside from recent levels.
The company's IP portfolio includes 12 patents granted globally and 57 patent applications pending.
Named Competitors
da Vinci Surgical System — Reusable robotic surgical platform for general surgery and specialties
Niobe ES — Robotic navigation system for interventional procedures
EXO-Suit — Exoskeleton robotics for rehabilitation and mobility
Recent Developments
(February 2026) LIBERTY System highlighted at leading vascular disease management conference
(February 2026) Limited Market Release on schedule with full market release prepared for Q2 2026
(January 2026) Emory University Hospital adopted LIBERTY as first hospital worldwide
(November 2025) Limited Market Release of LIBERTY System commenced in U.S.
Open the full interactive Microbot Medical Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.